Regulatory Information
HSA regulatory responsibility and product classification details
Regulatory Responsibility
Product Classification
Formulation Information
CREAM
**Dosage** Uncovered lesions: 2–3 daily applications. Covered lesions: Less frequent application may be adequate.
TOPICAL
Medical Information
**Indications** Fucicort® is indicated in inflammatory dermatoses where bacterial infection is present or likely to occur. Inflammatory dermatoses include atopic eczema, discoid eczema, stasis eczema, seborrhoeic, dermatitis, contact dermatitis, lichen simplex chronicus, psoriasis, discoid lupus erythematosus.
**Contra-indications** Hypersensitivity to fusidic acid/sodium fusidate, betamethasone valerate or to any of the Excipients. Due to the content of corticosteroid, Fucicort® is contraindicated in the following conditions: Systemic fungal infections Primary skin infections caused by fungi, virus or bacteria, either untreated or uncontrolled by appropriate treatment (see Special Warnings and Precautions for Use – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_) Skin manifestations in relation to tuberculosis, either untreated or uncontrolled by appropriate therapy. Perioral dermatitis and rosacea
D07CC01
betamethasone and antibiotics
Manufacturer Information
DKSH SINGAPORE PTE. LTD.
LEO Pharma A/S
LEO LABORATORIES LIMITED
Active Ingredients
Documents
Package Inserts
Fucicort Cream_PI.pdf
Approved: October 9, 2019